DC’s ‘Clayface’ Passes $100 Million After Being Officially Removed From 532 Theaters
DC’s Clayface crossed $100 million globally and achieved theatrical breakeven after dropping from 532 theaters, signaling a rare box-office milestone for a non-franchise horror entry. The film, produced on a modest budget of about $40 million, is outperforming some horror peers while lingering behind the year’s bigger superhero titles. It plays more like a standalone horror film than a superhero installment, with early momentum that later cooled as theaters reduced showings. Critics and audiences have largely responded positively, and the movie is positioned to influence DC Studios’ later, lower-budget rogues-gallery projects. A clearer path forward may involve leveraging its offbeat identity to fuel cost-effective future releases within the DCU.
Dive Deeper:
Clayface surpassed $100 million worldwide two weeks into its release while also dropping more than 530 theaters, a dramatic shift from its initial 3,458-location launch. The weekend added about $7 million domestically, pushing the U.S. total toward $60 million. Despite the sizable global milestone, the film’s domestic gross underscores a more modest footprint relative to major genre hits this year.
Budget-wise, Clayface is cited at around $40 million, a figure that sits below many contemporary horror productions but well above ultra-low-cost indie horror. Comparisons are drawn to titles like Scream 7 and Resident Evil in production cost, while Backrooms and Obsession are noted as lower-cost anomalies with outsized, global grosses. The piece references Joker as a high-water mark for horror-to-box-office efficiency, though it frames Clayface as a different kind of success.
The narrative emphasizes that Clayface operates outside of the DC movie universe’s typical superhero framework, aligning more with conventional horror than with a large-scale superhero franchise. This distinction shapes expectations for its performance against both horror and superhero benchmarks, and it informs industry speculation about future DC Studios projects that could emphasize cost effectiveness.
Box-office trajectory suggests Clayface may surpass The Mummy and Evil Dead Burn at the global level, reinforcing a pattern where lean-budget horror can reach sizable totals even without an expansive theatrical footprint. Domestic performance, however, remains more restrained, implying a split reception between global audiences and U.S. theatergoers.
Critical and audience reception is noted as positive, with the film earning a 78% Certified Fresh score on Rotten Tomatoes. The consensus highlights the movie’s unique DCU identity, its body-horror influences, and a payoff that becomes satisfyingly gruesome as the plot progresses. This reception supports expectations for continued discussion and visibility in Collider’s ongoing coverage.